摘要
目的观察细胞因子诱导杀伤细胞(cytokine induced killer cells)辅助治疗非霍奇金淋巴瘤的安全性及近期疗效。方法对6例经病理确诊为非霍奇金淋巴瘤并且存在结外器官侵犯的患者,取其自体外周血单个核细胞,在含10%血浆的RPMI-1640培养基中添加Anti-CD3mAb和rhIL-2联合诱导单个核细胞为CIK细胞,并将细胞进行自体回输。结果CIK细胞输注后可见患者体内CD3+CD56+细胞较前增加,影像学复查显示肿块缩小,治疗过程中主要出现畏寒、发热,未观察到其他明显副作用。结论自体单个核细胞可以高效扩增CIK细胞,回输治疗非霍奇金淋巴瘤安全有效,且无明显毒副作用。
Objective To evaluate the safety and therapeutic effect of Cytokine-induced killer（CIK） cells for non-Hodgkin lymphoma. Methods 6 NHL patients diagnosed pathologically with organs offended were collected. Peripheral blood MNC was cultured in the RPMI-1640 medium containing 10% serum,induced into CIK cells in the presence of rhIL-2 and anti-CD3mAb.Cultured auto-CIK cells of incubation were transfused back to the patient. Results After the CIK cells infusion,the patients＇ CD3^＋CD56^＋ cells increased.The diminution of tumor volume was observed by radiologic examination in all patients.Conclusion The results indicated that auto-CIK cells were expanded effectively, and the treatment of non-Hodgkin lymphoma is safe and effective, with few side effects.
出处
《中国血液流变学杂志》
CAS
2007年第1期61-63,共3页
Chinese Journal of Hemorheology
关键词
CIK细胞
免疫治疗
非霍奇金淋巴瘤
Cytokine induced killer（CIK）
Immunity treatment
Non-Hodgkin lymphoma
